Cargando…
Relevance of diffusion-weighted imaging with background body signal suppression for staging, prognosis, morphology, treatment response, and apparent diffusion coefficient in plasma-cell neoplasms: A single-center, retrospective study
Accurate staging and evaluation of therapeutic effects are important in managing plasma-cell neoplasms. Diffusion-weighted imaging with body signal suppression magnetic resonance imaging (DWIBS-MRI) allows for acquisition of whole-body volumetric data without radiation exposure. This study aimed to...
Autores principales: | Yamada, Akiko, Araki, Yoichi, Tanaka, Yuko, Otsuki, Shunsuke, Yamada, Arisa, Moriyama, Mitsuru, Katagiri, Seiichiro, Suguro, Tamiko, Asano, Michiyo, Yoshizawa, Seiichiro, Akahane, Daigo, Furuya, Nahoko, Fujimoto, Hiroaki, Okabe, Seiichi, Gotoh, Moritaka, Suzuki, Kunihito, Saito, Kazuhiro, Gotoh, Akihiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270139/ https://www.ncbi.nlm.nih.gov/pubmed/34242226 http://dx.doi.org/10.1371/journal.pone.0253025 |
Ejemplares similares
-
Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study
por: Katagiri, Seiichiro, et al.
Publicado: (2022) -
Cardiac biopsy with intracardiac echocardiographic guidance for successful diagnosis of cardiac lymphoma
por: Katagiri, Seiichiro, et al.
Publicado: (2018) -
Cholecystectomy in a patient with paroxysmal nocturnal haemoglobinuria undergoing ravulizumab maintenance treatment
por: Moriyama, Mitsuru, et al.
Publicado: (2021) -
Low body weight and body mass index may be associated with musculoskeletal pain following imatinib discontinuation in chronic myeloid leukemia
por: Katagiri, Seiichiro, et al.
Publicado: (2017) -
Gilteritinib Affects the Selection of Dominant Clones in Clonal Hematopoiesis: Sequential Genetic Analysis of an FLT3-ITD Positive AML Patient with Long-Term Gilteritinib Therapy
por: Katagiri, Seiichiro, et al.
Publicado: (2023)